Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Classificação em ações #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Preço da ação
$0.16328419
Valor de mercado
$204.14K
Variação (1 dia)
4.35%
Variação (1 ano)
102.45%
País
GB
Negociar Fusion Antibodies plc (FAB)

Categoria

Lucros da Fusion Antibodies plc (FAB)
Lucros em Sep 2025 TTM: $-2.06M
De acordo com os últimos relatórios financeiros da Fusion Antibodies plc, os ganhos atuais da empresa são de $-2.06M. Em 2024, a empresa teve ganhos de $-2.89M, um aumento em relação a aos ganhos de 2023, que foram de $-3.53M. Os ganhos apresentados nesta página são os ganhos antes de juros e impostos, conhecidos como EBIT.
Histórico de lucros da Fusion Antibodies plc de 2013 a 2026
Lucros no final de cada ano
Ano Lucros Alterar
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Lucros de empresas semelhantes ou concorrentes
Empresa Lucros Diferença de Lucros País
$20.46B -992,770.77%
DK
$4.64B -225,408.48%
US
$5.23B -253,916.57%
US
$2.14B -103,830.35%
BE
$1.45B -70,512.80%
NL